X4 Pharmaceuticals Completes Enrollment in Phase III Mavorixafor Trial in Patients with WHIM Syndrome

X4 Pharmaceuticals, Inc. announced that it has completed enrollment in the ongoing pivotal Phase II clinical trial of its lead candidate, mavorixafor, in the treatment of patients with genetically confirmed warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome, a primary immunodeficiency caused by gain-of-function mutations in the CXCR4 gene.